We couldn’t find any results matching your search.
Please try using other words for your search or explore other sections of the website for relevant information.
![](http://carpathians.online/777/templates/cheerup/res/banner1.gif)
We’re sorry, we are currently experiencing some issues, please try again later.
Our team is working diligently to resolve the issue. Thank you for your patience and understanding.
Bid Price and Ask Price
The bid & ask refers to the price that an investor is willing to buy or sell a stock. The bid is the highest amount that a buyer is currently willing to pay, whereas the ask is the lowest amount that a seller is currently willing to sell. The numbers next to the bid/ask are the “ size ”. The bid size displays the total amount of desired shares ... Read More. to buy at that price, and the ask size is the number of shares offered for sale at that price. The data displayed in the quote bar updates every 3 seconds; allowing you to monitor prices in real-time. The bid-ask spread can indicate a stock’s liquidity, which is how easy it is to buy and sell in the marketplace. Often, a smaller spread suggests higher liquidity, meaning more buyers and sellers in the market are willing to negotiate. In contrast, a larger spread suggests lower liquidity, as there are fewer investors willing to negotiate. You can use the bid-ask spread to determine whether to place a market order or limit order when trading, helping you to optimize your price and have a successful order execution. Real-time bid and ask information is powered by Nasdaq Basic, a premier market data solution. This data feed is available via Nasdaq Data Link APIs; to learn more about subscribing, visit Nasdaq Data Link's products page . ... Read Less.
![voyager therapeutics stock price voyager therapeutics stock price](https://www.nasdaq.com/themes/nsdq/src/assets/images/scorecard-lite-lock.png)
- After-Hours
- Press Releases
- Analyst Research
- Dividend History
- Historical Quotes
- Historical NOCP
- P/E & PEG Ratios
- Option Chain
- Short Interest
- Institutional Holdings
- Insider Activity
- SEC Filings
- Revenue EPS
Symbol Search
Recently viewed.
![voyager therapeutics stock price NPlus Promo Banner_v2](https://www.nasdaq.com/sites/acquia.prod/files/2023/10/20/Promo%20Banner_v2_0.png)
Analyze your stocks, your way
Leverage the Nasdaq+ Scorecard to analyze stocks based on your investment priorities and our market data.
Latest News
This data feed is not available at this time.
Trending Stocks
Trending etfs, trending indexes.
- Real-time Data is provided using Nasdaq Last Sale Data
Data provided by Nasdaq Data Link, a premier source for financial, economic and alternative datasets. Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. Register for your free account today at data.nasdaq.com .
- Type a symbol or company name. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return.
These symbols will be available throughout the site during your session.
Your symbols have been updated
Edit watchlist.
- Type a symbol or company name. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return.
Opt in to Smart Portfolio
Smart Portfolio is supported by our partner TipRanks. By connecting my portfolio to TipRanks Smart Portfolio I agree to their Terms of Use .
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here . By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service .
![voyager therapeutics stock price Zacks Investment Research Home](https://staticx.zacks.com/images/zacks/logos/zacks_logo_200x57.png)
Member Sign In
Don't Know Your Password?
![voyager therapeutics stock price Zacks](https://staticx.zacks.com/images/zacks/logos/zacks_logo_200x57.png)
- Zacks #1 Rank
- Zacks Industry Rank
- Zacks Sector Rank
- Equity Research
- Mutual Funds
- Mutual Fund Screener
- ETF Screener
- Earnings Calendar
- Earnings Releases
- Earnings ESP
- Earnings ESP Filter
- Stock Screener
- Premium Screens
- Basic Screens
- Thematic Screens
- Research Wizard
- Personal Finance
- Money Management
- Retirement Planning
- Tax Information
- My Portfolio
- Create Portfolio
- Style Scores
- Testimonials
- Zacks.com Tutorial
Services Overview
- Zacks Ultimate
- Zacks Investor Collection
- Zacks Premium
Investor Services
- ETF Investor
- Home Run Investor
- Income Investor
- Stocks Under $10
- Value Investor
- Top 10 Stocks
Other Services
- Method for Trading
- Zacks Confidential
Trading Services
- Black Box Trader
- Counterstrike
- Headline Trader
- Insider Trader
- Large-Cap Trader
- Options Trader
- Short Sell List
- Surprise Trader
- Alternative Energy
![voyager therapeutics stock price Zacks Investment Research Home](https://staticx.zacks.com/images/zacks/logos/logo2014_tagstack-sitehead_232x92_2x.png)
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK . If you do not, click Cancel.
Voyager Therapeutics (VYGR)
(delayed data from nsdq).
-0.02 (-0.31%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $6.46 -0.01 (-0.15%) 7:58 PM ET
Add to portfolio
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Education - Learn about the Zacks Rank
Zacks Rank Home - Zacks Rank resources in one place
Zacks Premium - The only way to fully access the Zacks Rank
3-Hold of 5 3
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Style Scores Education - Learn more about the Zacks Style Scores
F Value | F Growth | B Momentum | F VGM
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
Zacks Rank Education -- Learn more about the Zacks Rank Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank
Top 28% (70 out of 250)
Industry: Medical - Biomedical and Genetics
![voyager therapeutics stock price Zacks Premium Feature](https://staticx.zacks.com/images/zacks/icons/zp-_18x18a4x.png)
Quote Overview
Stock activity, key earnings data.
Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season.
The technique has proven to be very useful for finding positive surprises. In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest.
Visit the Earnings ESP Center
See the Full List of Stocks To Beat Earnings
This is an estimated date of earnings release. Neither Zacks Investment Research, Inc. nor its Information Providers can guarantee the accuracy, completeness, timeliness, or correct sequencing of any of the Information on the Web site, including, but not limited to Information originated by Zacks Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Information Providers, or gathered by Zacks Investment Research, Inc. from publicly available sources. There may be delays, omissions, or inaccuracies in the Information.
![](http://carpathians.online/777/templates/cheerup/res/banner1.gif)
Research Report for VYGR
![voyager therapeutics stock price voyager therapeutics stock price](https://staticx.zacks.com/images/zacks/buttons/report_common_btn.png)
News for VYGR
This file is used for Yahoo remarketing pixel add
Due to inactivity, you will be signed out in approximately:
Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.
Voyager Therapeutics Inc
Ever heard of finviz*elite.
Our premium service offers you real-time quotes, advanced visualizations, technical studies, and much more. Become Elite and make informed financial decisions.
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
![title= voyager therapeutics stock price](https://ir.voyagertherapeutics.com/sites/g/files/knoqqb89791/themes/site/client_site_202/local/images/hamburger-icon.png)
Vision, Mission, & Strategy
Management Team
Board of Directors
Scientific Advisory Board
Core Values
• VY7523 for Alzheimer’s
• Alzheimer’s early research
• SOD1 for ALS
Patient Resources
Partnerships
TRACER Platform
Non-Viral Delivery
Publications & Presentations
Press Releases
Events & Presentations
Stock Information
Shareholder Services
Job Openings
Our Community
Mission & Values
Disclosures
Stock Quote & Chart
Stock quote, stock chart.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Voyager Therapeutics Inc (VYGR)
- Performance
- Fundamental Chart
- Scatter Plot
- Stress Test
Price Chart
![voyager therapeutics stock price Advanced search](https://cdn.zonebourse.com/images/loupe_recherche.png)
English (USA)
![voyager therapeutics stock price English (UK)](https://cdn.zonebourse.com/images/png-country/24x24/gb.png)
English (UK)
![voyager therapeutics stock price English (Canada)](https://cdn.zonebourse.com/images/png-country/24x24/ca.png)
English (Canada)
![voyager therapeutics stock price English (India)](https://cdn.zonebourse.com/images/png-country/24x24/in.png)
English (India)
![voyager therapeutics stock price Deutsch (Deutschland)](https://cdn.zonebourse.com/images/png-country/24x24/de.png)
Deutsch (Deutschland)
![voyager therapeutics stock price Deutsch (Österreich)](https://cdn.zonebourse.com/images/png-country/24x24/at.png)
Deutsch (Österreich)
![voyager therapeutics stock price Deutsch (Schweiz)](https://cdn.zonebourse.com/images/png-country/24x24/ch.png)
Deutsch (Schweiz)
![voyager therapeutics stock price Español](https://cdn.zonebourse.com/images/png-country/24x24/es.png)
Français (France)
![voyager therapeutics stock price Français (Suisse)](https://cdn.zonebourse.com/images/png-country/24x24/ch.png)
Français (Suisse)
![voyager therapeutics stock price Italiano](https://cdn.zonebourse.com/images/png-country/24x24/it.png)
Nederlands (Nederland)
![voyager therapeutics stock price Nederlands (België)](https://cdn.zonebourse.com/images/png-country/24x24/be.png)
Nederlands (België)
![voyager therapeutics stock price voyager therapeutics stock price](https://cdn.zonebourse.com/images/png-country/24x24/us.png)
- Top Capitalization
- United States
- North America
- Middle East
- Sector Research
- Earnings Calendar
- Equities Analysis
- Most popular
- AMD (ADVANCED MICRO DEVICES)
- CARLSBERG A/S
- UBS GROUP AG
- NVIDIA CORPORATION
- STARBUCKS CORPORATION
- Index Analysis
- Indexes News
- EURO STOXX 50
- Currency Cross Rate
- Currency Converter
- Forex Analysis
- Currencies News
- Precious metals
- Agriculture
- Industrial Metals
- Livestock and Cattle
- CRUDE OIL (WTI)
- CRUDE OIL (BRENT)
- Yield Curve
- Developed Nations
- Emerging Countries
- South America
- Analyst Reco.
- Capital Markets Transactions
- New Contracts
- Profit Warnings
- Appointments
- Press Releases
- Security Transactions
- Earnings reports
- New markets
- New products
- Corporate strategies
- Legal risks
- Share buybacks
- Mergers and acquisitions
- Call Transcripts
- Currency / Forex
- Commodities
- Cryptocurrencies
- Interest Rates
- Asset Management
- Climate and ESG
- Cybersecurity
- Geopolitics
- Central Banks
- Private Equity
- Business Leaders
- All our articles
- Most Read News
- All Analysis
- Satirical Cartoon
- Today's Editorial
- Crypto Recap
- Behind the numbers
- All our investments
- Asia, Pacific
- Virtual Portfolios
- USA Portfolio
- European Portfolio
- Asian Portfolio
- My previous session
- My most visited
- Yield stocks
- Quality stocks
- Dividend Aristocrats
- Trend-Following Stocks
- Growth stocks
- Millennials
- The Golden Age of Video Games
- 3D Printing
- Israeli innovation
- Unusual volumes
- New Historical Highs
- New Historical Lows
- Top Fundamentals
- Sales growth
- Earnings Growth
- Profitability
- Rankings Valuation
- Enterprise value
- Top Consensus
- Analyst Opinion
- Target price
- Estimates Revisions
- Top ranking ESG
- Environment
- Visibility Ranking
- Stock Screener Home
- Strategic Metals
- Pricing Power
- Oversold stocks
- Overbought stocks
- Close to resistance
- Close to support
- Accumulation Phases
- Most volatile stocks
- Top Investor Rating
- Top Trading Rating
- Top Dividends
- Low valuations
- All my stocks
- Stock Screener
- Stock Screener PRO
- Portfolio Creator
- Event Screener
- Dynamic Chart
- Economic Calendar
- Our subscriptions
- Our Stock Picks
- Thematic Investment Lists
Voyager Therapeutics, Inc. Stock
Us92915b1061, biotechnology & medical research, valuation: voyager therapeutics, inc., chart: voyager therapeutics, inc., latest news: voyager therapeutics, inc., last transcript: voyager therapeutics, inc..
Analysts' recommendations: Voyager Therapeutics, Inc.
Press releases: voyager therapeutics, inc., news in other languages: voyager therapeutics, inc., quotes and performance, course extremes.
![voyager therapeutics stock price Extreme 6.37](https://www.marketscreener.com/images/extremecours_fleche.png)
Managers and Directors: Voyager Therapeutics, Inc.
Etfs: voyager therapeutics, inc., other biotechnology & medical research, company profile.
Delayed Quote Nasdaq, August 16, 2024 at 04:00 pm EDT
Income Statement and Estimates
Analysts' consensus, quarterly earnings, rate of surprise.
- Stock Market
- Voyager Therapeutics-stock
- News for Voyager Therapeutics
Buy Rating Affirmed for Voyager Therapeutics on Robust Pipeline and Strong Financial Position
Analyst Sumant Kulkarni of Canaccord Genuity maintained a Buy rating on Voyager Therapeutics ( VYGR – Research Report ), retaining the price target of $14.00.
Sumant Kulkarni has given his Buy rating due to a combination of factors surrounding Voyager Therapeutics’ promising developments in its pipeline. The company’s innovative approach includes an anti-tau antibody for Alzheimer’s disease and gene therapy programs for both Alzheimer’s and amyotrophic lateral sclerosis, leveraging their proprietary TRACER capsid platform. Kulkarni sees great potential in the tau-targeting strategies and gene therapy programs. Furthermore, the company’s TRACER technology is also encouraging external partnerships, indicating a positive outlook for the company’s collaborative efforts. Moreover, Kulkarni notes that while the visibility on the external programs is moderate, they seem to be advancing steadily. Voyager Therapeutics’ financial position, with enough funding to carry it into 2027, is considered strong, which could allow the company to continue its research and development efforts without immediate financial pressure. Looking ahead, a busy year is anticipated in 2025 with expected safety and pharmacokinetic data from Phase 1 studies and the filing of investigational new drug applications. These milestones could potentially drive the stock’s performance in the medium to long term, which supports the analyst’s Buy recommendation.
In another report released on August 8, Oppenheimer also maintained a Buy rating on the stock with a $18.00 price target.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Voyager Therapeutics (VYGR) Company Description:
Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene theraphy programs include VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guangping Gao, Mark A. Kay, Krystof Bankiewicz and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.
Read More on VYGR:
- Voyager Therapeutics price target lowered to $7 from $8 at Wedbush
- Voyager Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase
- Voyager Therapeutics reports Q2 EPS (18c), consensus (41c)
- Voyager Therapeutics Reports Second Quarter 2024 Financial and Operating Results
- VYGR Upcoming Earnings Report: What to Expect?
Voyager Therapeutics News MORE
Related stocks.
Theriva Biologics Announces Reverse Stock Split
ROCKVILLE, Md., Aug. 16, 2024 (GLOBE NEWSWIRE) — Theriva Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, announced today a reverse stock split of its issued and outstanding common stock, par value $0.001 per share, at a ratio of one (1) share of common stock for every twenty five (25) shares of common stock, effective as of 12:01 a.m. (Eastern Time) on August 26, 2024 (the “Effective Date”). The Company’s common stock will begin trading on a split-adjusted basis when the market opens on August 26, 2024. The reverse stock split was authorized by the Company’s Board of Directors on August 15, 2024. Pursuant to the laws of the State of Nevada, the Company’s state of incorporation, the Company’s Board of Directors has the authority to effect a reverse stock split without shareholder approval if the number of authorized shares of common stock and the number of outstanding shares of common stock are proportionally reduced. The Company will file a certificate of change to its articles of incorporation, as amended, with the Secretary of State of Nevada to effect the reverse stock split. The Company’s common stock will continue to trade on the NYSE American under the stock ticker “TOVX” but will trade under the new CUSIP number 87164U 508.
As a result of the reverse split, each twenty five (25) pre-split shares of common stock outstanding will automatically combine into one (1) new share of common stock without any action on the part of the holders, and the number of outstanding common shares will be reduced from 25,131,230 shares to 1,005,249 shares without taking into account fractional shares.
The reverse stock split is being effected to ensure that the Company can meet the per share price requirements of the NYSE American, the Company's current listing exchange.
No fractional shares will be issued as a result of the reverse stock split. Shareholders who otherwise would be entitled to a fractional share because they hold a number of shares not evenly divisible by the 1 (one) for twenty five (25) reverse split ratio, will automatically be entitled to receive an additional fractional share of the Company’s common stock to round up to the next whole share.
The Company’s transfer agent, Equiniti Trust Company, which is also acting as the exchange agent for the reverse split, will send instructions to stockholders of record who hold stock certificates regarding the exchange of their old certificates for new certificates, should they wish to do so. Stockholders who hold their shares in brokerage accounts or “street name” are not required to take action to effect the exchange of their shares.
About Theriva™ Biologics, Inc.
Theriva™ Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient’s immune system. The Company’s lead candidates are: (1) VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment; (2) SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci) and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients; and (3) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases. For more information, please visit Theriva Biologics’ website at www.therivabio.com.
Forward-Looking Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions, and include statements regarding our planned stock split. These forward-looking statements are based on management's expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the stock split having the desired effect, t he ability to continue to enroll patients as planned, generating clinical data that establishes VCN-01 may lead to improved clinical outcomes for patients with PDAC and other solid cancers; the Company’s and VCN’s product candidates demonstrating safety and effectiveness, as well as results that are consistent with prior results; the ability to complete clinical trials on time and achieve the desired results and benefits; the ability to obtain regulatory approval for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to the Company’s and VCN’s ability to promote or commercialize their product candidates for the specific indications, acceptance of product candidates in the marketplace and the successful development, marketing or sale of the Company’s and VCN’s products, developments by competitors that render such products obsolete or non-competitive, the Company’s and VCN’s ability to maintain license agreements, the continued maintenance and growth of the Company’s and VCN’s patent estate, the ability to continue to remain well financed and other factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 and its other filings with the SEC, including subsequent periodic reports on Forms 10-Q and current reports on Form 8-K. The information in this release is provided only as of the date of this release, and Theriva Biologics undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
For further information, please contact:
Investor Relations:
Chris Calabrese
LifeSci Advisors, LLC
917-680-5608
![](http://carpathians.online/777/templates/cheerup/res/banner1.gif)
IMAGES
COMMENTS
Find the latest Voyager Therapeutics, Inc. (VYGR) stock quote, history, news and other vital information to help you with your stock trading and investing.
Voyager Therapeutics stock price target cut to $16 from $37 at Instinet. Mar. 30, 2020 at 7:59 a.m. ET by Tomi Kilgore. Voyager Therapeutics started at buy with $18 stock price target at Benchmark.
Get the latest Voyager Therapeutics Inc (VYGR) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
Voyager Therapeutics shares soar 32% on news of deal with Novartis that includes up to $1.2 billion in milestone payments. Voyager Therapeutics Inc.'s stock VYGR, -4.20% soared 32% early Tuesday, after the Lexington, Mass.-based biotech announced a new license agreement with Novartis Pharma AG, a unit of Novartis AG. Other symbols: NVS.
A high-level overview of Voyager Therapeutics, Inc. (VYGR) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
Discover real-time Voyager Therapeutics, Inc. Common Stock (VYGR) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Stay ahead with Nasdaq.
View Voyager Therapeutics, Inc VYGR investment & stock information. Get the latest Voyager Therapeutics, Inc VYGR detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.
View the latest Voyager Therapeutics Inc. (VYGR) stock price, news, historical charts, analyst ratings and financial information from WSJ.
Voyager Therapeutics to Present at Multiple Virtual Investor Conferences. Find the latest Voyager Therapeutics, Inc. (VYGR) stock quote, history, news and other vital information to help you with your stock trading and investing.
Real time Voyager Therapeutics (VYGR) stock price quote, stock graph, news & analysis.
The latest Voyager Therapeutics stock prices, stock quotes, news, and VYGR history to help you invest and trade smarter.
VYGR Competitors. $ Market cap P/E ratio $ Price 1d change 52-week range. View Voyager Therapeutics, Inc. VYGR stock quote prices, financial information, real-time forecasts, and company news from ...
Voyager Therapeutics and Novartis Sign Deal for Neurological Disease Treatments. (Investopedia) 10:46AM. VYGR Stock Alert: The $1.2 Billion Reason Voyager Therapeutics Is Up Today. (InvestorPlace) 07:36AM. UPDATE 2-Novartis signs gene therapy deal with Voyager for $100 mln upfront.
Stock Quote. Change. Volume. Today's Open. Previous Close. Today's High. Today's Low. 52 Week High. 52 Week Low. Stock Chart. Data Provided by Refinitiv. Minimum 15 minutes delayed. Voyager Therapeutics Inc. • ... Voyager Therapeutics, Inc. 75 Hayden Avenue Lexington, MA 02421 857.259.5340
See the latest Voyager Therapeutics Inc stock price (VYGR:XNAS), related news, ... Voyager Therapeutics shares soar 32% on news of deal with Novartis that includes up to $1.2 billion in milestone ...
In depth view into VYGR (Voyager Therapeutics) stock including the latest price, news, dividend history, earnings information and financials. Voyager Therapeutics Inc (VYGR) 8.29 -0.39 ( -4.49% ) USD | NASDAQ | Aug 02, 16:00
Complete Voyager Therapeutics Inc. stock information by Barron's. View real-time VYGR stock price and news, along with industry-best analysis.
Voyager Therapeutics, Inc. (NASDAQ:VYGR) posted its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.18) earnings per share for the quarter, beating analysts' consensus estimates of ($0.38) by $0.20. The firm earned $29.58 million during the quarter, compared to analysts' expectations of $11.52 million.
Voyager Therapeutics. VYGR. $8.30. -0.38 (-4.38%) Share Price. as of August 2 4:00:00 PM EST. Voyager Therapeutics (VYGR) Stock Price Performance. Voyager Therapeutics (VYGR) Stock Key Data ...
Discover historical prices for VYGR stock on Yahoo Finance. View daily, weekly or monthly format back to when Voyager Therapeutics, Inc. stock was issued.
As you might know, Voyager Therapeutics, Inc. (NASDAQ:VYGR) just kicked off its latest quarterly results with some very strong numbers. Revenue crushed expectations at US$30m, beating expectations ...
Voyager Therapeutics, Inc. (VYGR.NASDAQ): Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Voyager Therapeutics, Inc. | Nasdaq: VYGR | Nasdaq. ... Voyager Therapeutics, Inc. is a biotechnology company focused on advancing neurogenetic medicines. The Companyâ s pipeline includes programs for Alzheimerâ s ...
We've gathered analysts' opinions on Voyager Therapeutics, Inc. future price: according to them, VYGR price has a max estimate of 30.00 USD and a min estimate of 7.00 USD. Watch VYGR chart and read a more detailed Voyager Therapeutics, Inc. stock forecast: see what analysts think of Voyager Therapeutics, Inc. and suggest that you do with its ...
Analyst Sumant Kulkarni of Canaccord Genuity maintained a Buy rating on Voyager Therapeutics (VYGR - Research Report), retaining the price target of $14.00. Sumant Kulkarni has given his Buy ...
Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of - and ultimately cure - neurological diseases.
Voyager Therapeutics stock pops 30% on deal with Novartis ; Several equities research analysts have recently commented on VYGR shares. Wedbush reduced their price target on shares of Voyager Therapeutics from $8.00 to $7.00 and set a "neutral" rating for the company in a research report on Wednesday, August 7th.
Track Voyager Therapeutics Inc (VYGR) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors ... VYGR Voyager Therapeutics Inc. 3,767. Market Cap: $361.56M: Volume: 477,032.00: 52-Wk High: $11.72: 52-Wk Low ...
Voyager Therapeutics : ... CRSP's average price-to-sales ratio stood at 27.09. ... While SPRT stock has been a strong performer this year, the market fallout has negatively impacted the company ...
ROCKVILLE, Md., Aug. 16, 2024 (GLOBE NEWSWIRE) — Theriva Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, announced today a reverse stock split of its issued and outstanding common stock, par value $0.001 per share, at a ratio of one (1) share of common stock for every twenty five (25 ...